Skip to Main Content

Life sciences venture investment looks like it’s having a good run so far this year, according to a new report from CB Insights and PwC.

Of course, much of that boost is coming from hefty investments in Grail and Vir Biotechnology ($900 million and $150 million, respectively). Absent that, the numbers fail to dazzle quite so much.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!